Clinical Trials Logo

Endometriosis clinical trials

View clinical trials related to Endometriosis.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06438744 Recruiting - Clinical trials for Endometriosis-related Pain

The Role of Thread Embedding Acupuncture for Pain and Quality of Life in Endometriosis Patients

Start date: December 18, 2023
Phase: N/A
Study type: Interventional

Endometriosis is a common gynecological problem, with pain as the main problem. Pain can be felt for years, in high intensity, continuous, unpredictable, and disrupts the patient's daily life, thereby reducing the quality of life. Dienogest is a progestin-derived drug, the first line therapy for endometriosis pain. Other therapy options include hormonal, non-hormonal therapy, and surgery, but they have a high risk of side effects and recurrence. In cases of endometriosis, acupuncture has an analgesic effect, modulates hormones and neurotransmitters, strengthens immune cells, and reduces inflammation, therefore improves quality of life. However, the effectiveness of thread embedding acupuncture for endometriosis pain is still rarely published. This research was conducted to determine the effectiveness of thread embedding acupuncture for pain and quality of life in endometriosis patients.

NCT ID: NCT06426420 Recruiting - Endometriosis Clinical Trials

Endometriosis and ATR-FTIR Spectroscopy

Start date: September 15, 2022
Phase: N/A
Study type: Interventional

The goal of this study is to explore the use of mid-infrared spectroscopy (ATR-FTIR) as a detection tool for endometriosis in urine.

NCT ID: NCT06414720 Recruiting - Endometriosis Clinical Trials

Salivary microRNA in Endometriosis: Correlation With Response to Progestin Therapy

ENDOmiRNA
Start date: April 22, 2024
Phase:
Study type: Observational

This study aims to analyze the salivary miRNA specific for patients diagnosed with endometriosis, specifically evaluating the miRNA profile of patients who respond versus those who do not respond to progestin therapy. Ninety patients attending the Chronic Pelvic Pain Clinic will be recruited, and they will be asked to provide a saliva sample before starting medical therapy. The response to the therapy will be evaluated after 4 months from the beginning of the therapy itself.

NCT ID: NCT06414083 Recruiting - Endometriosis Clinical Trials

Histologic Comparison of Ablative Techniques for Endometriosis

Start date: May 9, 2024
Phase: N/A
Study type: Interventional

To our knowledge, no other human studies directly compare the effectiveness of the various ablative technologies. We set out to design a study to directly compare ablative energy sources and evaluate their ability to destroy native endometriosis tissue in humans.

NCT ID: NCT06413381 Recruiting - Endometriosis Clinical Trials

RISK FACTORS FOR NON-RESPONSE TO HORMONAL MEDICAL THERAPY IN PATIENTS WITH ENDOMETRIOSIS

Start date: April 19, 2024
Phase:
Study type: Observational

Determine the proportion of patients with endometriosis unresponsive to medical therapy and to compare the clinical and ultrasonographic characteristics of this group of patients (study group) with the clinical and ultrasonographic characteristics of patients responsive to medical therapy (control group).

NCT ID: NCT06386276 Recruiting - Surgery Clinical Trials

Surgical TReatment of Women With Deep ENDometriosis

TrEnd
Start date: October 11, 2023
Phase:
Study type: Observational [Patient Registry]

TrEnd trial is aimed to collect data from consecutive patients undergoing segmental sigmoid colon/rectal resection for deep endometriosis. The main purpose of this project is to gather a large series of cases treated using standardized surgical procedures, allowing a precise evaluation of complications and long-term outcomes.

NCT ID: NCT06375811 Recruiting - Infertility Clinical Trials

Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp

PREGnant
Start date: March 16, 2024
Phase: Phase 3
Study type: Interventional

A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those pretreated with GnRH antagonist compared to those not pretreated with GnRH antagonist.

NCT ID: NCT06333353 Recruiting - Pain Clinical Trials

Is Repetitive Transcranial Magnetic Stimulation Effective in Reducing Endometriosis-associated Pain

Start date: April 12, 2024
Phase: N/A
Study type: Interventional

The goal of this research is to improve pain outcomes for the over 500K Canadian women, girls and gender-diverse individuals who are newly diagnosed with endometriosis each year. Chronic pain that persists after interventions for endometriosis is a huge problem. There is some evidence that endometriosis-associated pain (EAP) is, at least to some extent, associated with changes in pain physiology, particularly central sensitization of pain. There is currently no effective evidence-informed intervention that addresses EAP. Yet a recent feasibility trial on a repetitive transcranial magnetic stimulation (rTMS) intervention demonstrated promising results compared to a sham intervention for reducing pain in a sample with EAP. The objectives of this trial are: 1. to evaluate the effectiveness of an rTMS intervention for pain reduction among those with recalcitrant post-operative EAP, 2. to inform on the utility of a long (10 session) vs short (5 session) protocol for pain reduction among those with recalcitrant post-operative EAP 3. to determine if any improvements in pain observed 30 days after an rTMS intervention are retained 6 months later 4. to identify physical and psychosocial mediators that impact the successful reduction of pain among patients with EAP treated using rTMS. 5. to describe patients' perceptions of and satisfaction with rTMS as an intervention for EAP.

NCT ID: NCT06314126 Recruiting - Endometriosis Clinical Trials

Evaluation of D-Chiro-Inositol Treatment in Women With Endometriosis

ENDO-DCI
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

To date, the treatment for endometriosis is represented by the surgical removal of the lesions. Nonetheless, in the years following surgery, the lesions can recur, often due to excessive estrogen production. To balance estrogen, progestin- or estrogen-progestin-based medications are generally prescribed. On the other hand, progestins and estrogen-progestins act as contraceptives, preventing the onset of a pregnancy. At the same time, these can have side effects that can affect up to 30% of patients. For these and other reasons, some women refuse therapy with progestins or estrogen-progestins, preferring to resort to no treatment. Considering the need to research effective molecules in the prevention of relapses that can maintain fertility and avoid unwanted effects, the research focuses on natural molecules, well tolerated by the body. D-Chiro-Inositol (DCI) is a polyol normally present in human cell membranes, where, from a metabolic point of view, it acts as a second messenger of insulin, while from a hormonal point of view, it exerts an on the biosynthesis of androgens. This effect on steroidogenesis can be attributed to more than one mechanism. In the ovary, DCI stimulates direct testosterone production. Furthermore, it stimulates the accumulation of testosterone by reducing the activity of the aromatase enzyme, responsible for the conversion of androgens into estrogens. Considering the responsiveness of endometriosis to estrogens, and that these constitute a risk factor for recurrences following surgical removal, the use of DCI could be interesting from a clinical point of view. The study plans to verify whether D-Chiro-Inositol dietary supplementation can be effective in reducing systemic estrogen levels in women with endometriosis, thus also reducing the risk of relapses and associated symptoms.

NCT ID: NCT06313411 Recruiting - Clinical trials for Endometriosis Pelvic

How do I Perform a Laparoscopic Removal of a Pelvic Retroperitoneal Schwannoma

PRS
Start date: November 23, 2022
Phase:
Study type: Observational

Schwannomas are mainly benign tumors, which develop mainly in the skull or in the cervical region. Retroperitoneal location is rare, since it represents between 0.5 and 5% of scwhanomas. The malignant retroperitoneal form is, however, more common than in other locations. Retroperitoneal schwannoma is often discovered during the exploration of unexplained lumbo-pelvic pain, or in the face of compression of nearby organs. Abdominopelvic CT and magnetic resonance imaging are essential to characterize the mass and verify its extension. The precise diagnosis is based on the pathological examination of the part, and complete surgical excision is the standard treatment. Acquiring the surgical techniques and skills necessary to carry out these types of procedures is essential to providing optimal patient care.